Rieger Jayson bought 5,000 shares of Verrica Pharmaceuticals Inc. at $4.91 for $24.6k on Aug 17, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
CEO and President
CEO and President
Filed Aug 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$24,550Shares × reported price
Shares traded
5,000Common Stock
Price per share
$4.91Reported price. Read footnotes for ranges.
% of reported position traded
2.47%This security and ownership context
Holdings after
207,593Direct
Trade date
Aug 17, 2026Buy
Filed
Aug 18, 2026, 5:00 PM ET1-day reporting delay
Accession
0002043558-26-000005Code P · Transaction 2958
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 202,593 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 14, 2026Buy20,000$5.06$101,200Trade 2957
2 transaction rows in this filing. Joint filers share the same rows.

VRCA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
VRCA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +19%1w ago +9.4%1d ago +6.2%
Returns since7d +6%30d −3.2%90d180d1y

Footnotes in full

F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.04 to $5.088 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.